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Edited by Gerrit van MeerAbstract Experiments with multidrug resistance-associated
protein 1 (MRP1) showed 10-years ago that transport of vincris-
tine (VCR) by MRP1 could be stimulated by GSH, and trans-
port of GSH by VCR. Since then many examples of stimulated
transport have been reported for MRP1, 2, 3, 4 and 8. We discuss
here three models to explain stimulated transport. We favour a
model in which a large promiscuous binding site can bind more
than one ligand, allowing cooperative/competitive interactions
between ligands within the binding site. We conclude that there
is no unambiguous proof for co-transport of two diﬀerent ligands
by MRPs, but that cross-stimulated transport can explain the
published data.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: ABC transporters; Homotropic cooperativity;
Heterotropic cooperativity; Transport kinetics; MRPs1. Introduction
Drug transporters belonging to the ATP-binding cassette
(ABC) transporter families are able to transport drugs
against steep drug concentration gradients at the expense of
ATP hydrolysis. These transporters were discovered by their
ability to make cells resistant to large amphipathic anticancer
drugs, arsenite or toxic organic anions. Some of these trans-
porters are now also known to play an important role in the
defense of mammals against xenotoxins. The ABCB1 P-gly-
coprotein, the ABCG2 Breast Cancer Resistance Protein,
and the ABCC2 Multidrug Resistance Protein 2 (MRP2)
are present in the apical membrane of the gut mucosa and
they inhibit entry of xenotoxins into the body. These trans-
porters also guard vital body compartments against toxins,
such as the brain (ABCB1), the fetus (ABCB1 and ABCG2),
the germ line (ABCB1, ABCC1), the haemopoietic stem cells
(ABCB1, ABCG2, ABCC1), etc.
One of the largest sub-families of the ABC transporters, able
to aﬀect drug disposition, is the ABCC (MRP) family. There
are now 9 MRP family members and 8 of these (MRP1–8) are*Corresponding author. Fax: +31 20 669 1383.
E-mail address: p.borst@nki.nl (P. Borst).
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doi:10.1016/j.febslet.2005.12.039known tobe organic anion transporters. OnlyMRP9 (ABCC12)
is still without known substrate. Between them the 8 MRPs can
transport a remarkable range of organic anions, including anio-
nic drugs and drugs conjugated to glutathione, sulfate or glucu-
ronate. In addition, selected MRPs may transport a variety of
endogenous compounds, such as leukotrieneC4 (MRP1), biliru-
bin glucuronides (MRP2, MRP3), prostaglandins E1 and E2
(MRP4), cGMP (MRP4,MRP5,MRP8), and several glucuron-
osyl-, or sulfatidyl steroids.No twoMRPs have exactly the same
substrate speciﬁcity or tissue distribution and the precise func-
tion of most of the MRPs remains to be established. As the
MRPs have been reviewed by us1 [1–5,43] and others [6–12] in
recent years, we focus here onone controversial issue that should
be of interest to biochemists: the apparent ability of someMRPs
to mediate co-transport of two compounds.2. Initial experiments supporting co-transport
Early work on MRP1-mediated drug resistance showed that
resistance to neutral drugs, such as anthracyclines or Vinca
alkaloids, required cellular GSH. This led to the suggestion
that MRP1 exports these drugs from the cell together with
GSH. Apparent support for this idea came from vesicular
transport experiments mainly done in the labs of Deeley and
Cole and thoroughly reviewed in Deeley and Cole [13]. Loe
et al. [14,15] showed that vincristine (VCR) transport by
MRP1 is dependent on physiological (mM) concentrations of
GSH. Reciprocally, VCR stimulates GSH transport and low-
ers the Km for GSH from >1 mM to 100 lM. The presence
of GSH increases the aﬃnity of MRP1 for VCR 50-fold. For
technical reasons it was not possible to demonstrate that
VCR and GSH are co-transported by MRP1, but the co-trans-
port interpretation made sense. Molecules, such as LTC4, in
which an organic moiety is covalently linked to GSH, are eﬃ-
ciently transported by MRP1. Co-transporting an organic
moiety, such as VCR, together with GSH looked like a plausi-
ble alternative. However, other models can explain these re-
sults as well, as we show below.1Borst, P. and Wielinga, P. Pumping out drugs: the potential impact of
abc transporters on resistance to base, nucleoside, and nucleotide
analogs in: Deoxynucleoside Analogs in Cancer Therapy (Peters, G.J.,
Ed.), Humana Press, Totowa, in press.
blished by Elsevier B.V. All rights reserved.
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The stimulatory eﬀect of compound M (modulator) on the
transport of compound S (substrate) can be explained by the
three diﬀerent models illustrated in Fig. 1:
A. Co-transport
Compound M is required for transport of S and vice versa.
Transport occurs either from a single site (as drawn in
Fig. 1A), or from separate transport sites that both must be
occupied to get coupled transport. The stoichiometry of M
and S cotransport is deﬁned and a mechanistic property of
the system.
B. Heterotropic/homotropic cooperativity.
Compound M binds to an allosteric site in the transporter
and binding of M increases the aﬃnity of the transport site
for S (heterotropic cooperativity or stimulated transport). M
may not be transported at all, as shown in Fig. 1B. If S can
also bind to the M-site, it may stimulate its own transport
(homotropic cooperativity).
C. Membrane eﬀects on transporter structure.
Compound M alters the membrane environment of the
transporter resulting in an increased aﬃnity of the transportFig. 1. Models explaining stimulated transport by MRPs. See text for
explanation.M is amodulator binding to a sitemodulating the transport
of substrate S, but it can also be a (co-) substrate as in panel A.site for S, as shown in Fig. 1C. This possibility should be espe-
cially considered when one studies amphipathic modulators
known to partition substantially into the membrane [16].4. An evaluation of transport models
Each of the models in Fig. 1 makes predictions, although we
admit that none of the predictions is strong enough to rigor-
ously eliminate a model. The simple version of model A pre-
dicts that M and S are transported in a ﬁxed stoichiometry
(symport). This does not need to be 1:1, as it is conceivable
that two M could be transported for one S. Pure co-transport
without allosteric activation of one transport site by the other,
is most easily pictured in a single large cavity binding both M
and S, as shown in Fig. 1A. It should be noted, however, that
there are alternative versions of model A (Fig. 1A) in which
precise stoichiometry is lost:
a. Compound M is not strictly required for transport of S, but
two solutes M and S are needed to complete the transloca-
tion cycle (single turnover). The stoichiometry of M and S
co-transport will depend on the aﬃnity constants of the
transporter for these solutes and the ratio of M and S in
the medium, and thus reﬂects a kinetic property. This can
still be co-transport, but mechanistically this is very diﬀer-
ent from the obligatory co-transport pictured in Fig. 1A.
b. The observed stoichiometry could be aﬀected by diﬀerential
leak, i.e., if one of the two components has a greater ten-
dency for futile cycling than the other.
Model B is the most ﬂexible. It can explain apparent co-
transport by assuming that compounds S and M are both sub-
strate and modulator and that S andM can alternate in binding
to the S and M sites.This is shown schematically in Fig. 2B.
Some similarity between S and M sites follows from the pub-
lished results: as will be discussed in Section 6, E217bG binds
both to the S andM sites of MRP2 and manyMRP2 substrates
will stimulate transport of low concentrations of E217bG
[17,18]. Likewise, GSH is a substrate of MRP1 and stimulates
transport of several other substrates. The fact that the increased
transport of both VCR and GSH byMRP1, if both compounds
are present, is accompanied by a major increase in aﬃnity for
GSH is compatible with an altered MRP1 conformation when
VCR is bound [13]. The compounds that stimulate E217bG
transport by MRP2, also do so by increasing the aﬃnity for
E217bG without changing Vmax (see Section 6). Obviously, if
the binding sites for S and M resemble each other, the same
compound (S) could bind to both sites resulting in homotropic
cooperativity (Fig. 1B). Similarly M may compete with S at
higher M concentrations and thereby inhibit transport of S,
as shown for indomethacin in Fig. 4.
Model C makes the strong prediction that compound M
should aﬀect membrane structure. It seems doubtful whether
the very hydrophilic and acidic GSH would partition strongly
in the membrane and thereby aﬀect the transport. On the other
hand, anionic molecules with a signiﬁcant hydrophobic func-
tionality (many MRP substrates) are likely to do so.
It has been diﬃcult to study membrane eﬀects in drug trans-
porters, but the potential importance of such eﬀects can be
gleaned from a diﬀerent class of ABC-transporter, the bacterial
transporter Opu A (reviewed in [19]). When the bacteria are
transferred to hyperosmotic medium, this transporter catalyses
uptake of glycine betaine resulting in an increase of the inter-
Fig. 2. Models showing how apparent cotransport would be explained
according to the models presented in Fig. 1. (A) Obligatory cotrans-
port. Compound M is required for transport of S and vice versa. (B)
Heterotropic cooperativity. Compounds S and M are both substrate
and modulator and S and M alternate in binding to the S and M sites.
(C) Membrane eﬀects. Compounds S and M are both substrates. M
modulates transport of S andM by altering the membrane environment
of the transporter, resulting in increased transport of both S and M.
P. Borst et al. / FEBS Letters 580 (2006) 1085–1093 1087nal osmolality. Vesicular transport studies have shown that the
relation between transport rate and delta osmolality (the posi-
tive diﬀerence in osmolality outside and inside the vesicles) is
not hyperbolic, but an S-curve. The lag at low delta osmolality,
called the activation threshold, is dependent on the composi-
tion of the membrane in which the transporter is embedded.
The activation threshold increases with an increasing fraction
of anionic lipid and this appears to be due to multiple (electro-
static) interactions between anionic lipid and transporter pro-
tein. By raising ionic strength these interactions are broken
and the transporter is immediately switched on. A larger anio-
nic lipid fraction results in more extensive lipid–protein inter-
actions, which require more salt to disrupt the electrostatic
interactions, explaining the eﬀect of lipids on activation thresh-
old [19]. Importantly, not only charged lipids but also charged
amphipaths aﬀect the activation of the transporter. This ele-
gant system shows that some ABC-transporters are exquisitely
sensitive to the composition of the membrane in which they are
embedded and that changes in membrane composition can af-
fect transport by changing transporter conformation.Obviously, the models presented in Fig. 1 are three extreme
versions. There could be more than one transport site without
co-transport. There could be two transport sites showing allo-
steric interaction. There could be membrane eﬀects superim-
posed on models A or B. The models only provide a handle
to analyze the data.5. MRP1
Although early experiments suggested that MRP1 co-trans-
ports vincristine and GSH, subsequent work in the labs of
Cole and Deeley [13] has shown that transport by MRP1 is
more complex than initially thought. Four observations stand
out:
1. GSH can also stimulate transport of some organic anions
by MRP1. Examples are etoposide glucuronide [20] and es-
trone-3-sulfate [21]. Transport of 4-(methylnitrosamino)-1-
(3-pyridyl)-butanol-O-glucuronide (NNAL-O-gluc) [22]
and DHEAS [23] is even completely dependent on GSH.
The GSH is therefore not merely required to provide a neg-
atively charged moiety. It is also not required to provide a
sulfur atom, as GSH analogs not containing sulfur, like
ophthalmic acid, can completely replace GSH.
2. Whereas transport of estrone-3-sulfate and NNAL-O-gluc
was strongly stimulated by GSH, these substrates had no
detectable eﬀect on GSH transport [21].
3. Loe et al. [24] found that Verapamil stimulates transport of
GSH by MRP1. Whereas no GSH transport was detectable
in the absence of Verapamil, vesicular uptake of GSH was
substantial (Km = 0.1 mM; Vmax = 55 pmol/mg protein/
min) in the presence of 100 lM Verapamil. As no transport
of Verapamil by MRP1 was detectable with and without
GSH, there appeared to be no co-transport of GSH and
Verapamil. The authors point out, however, that the hydro-
phobic Verapamil could undergo futile recycling in the
membrane, or be released on the cis-side of the membrane.
Verapamil was also unable to inhibit transport of other
MRP1 substrates, such as LTC4, unless GSH was present.
Analysis of Verapamil analogs yielded one that inhibited
LTC4 transport up to 90% in the presence of GSH, without
signiﬁcantly stimulating GSH transport by MRP1 [25],
showing that it is possible to dissociate the two eﬀects of
Verapamil analogs.
4. Leslie et al. [26] found that several ﬂavonoids stimulate
GSH transport by MRP1 very strongly. Like Verapamil,
the ﬂavonoids do not appear to be transported by MRP1.
‘‘Our results suggest that ﬂavonoids stimulate MRP1-med-
iated GSH transport by increasing the apparent aﬃnity of
the transporter for GSH but provide no evidence that a
co-transport mechanism is involved’’ [26].
The initial results indicating co-transport of neutral MRP1
substrates with GSH still stand, but given the newer results
discussed in points 1–4, other interpretations of these experi-
ments should be considered. As Deeley and Cole [13] put it:
‘‘Overall, the data are consistent with the existence of a site
or sites on MRP1 capable of binding free GSH and certain
non-sulfhydryl-reducing analogues. They also indicate that
there is positive cooperativity between the interaction of
GSH (or related molecule) and the second substrate with
the protein. What remains unclear at present is why in some
1088 P. Borst et al. / FEBS Letters 580 (2006) 1085–1093cases both the second substrate and GSH are transported,
while in others, it appears that transport of only one or the
other substrate occurs.’’6. MRP2
Stimulated transport by MRP2 was ﬁrst observed by Ba-
kos et al. [27]. Using N-ethylmaleimide glutathione (NEM-
GS) as substrate, they found up to 3-fold stimulation of
transport by sulﬁnpyrazone and penicillin G and a lower
stimulation by indomethacin. GSH had no eﬀect on NEM-
GS transport. At higher sulﬁnpyrazone or indomethacin con-
centrations the stimulated NEM-GS was inhibited. This inhi-
bition is not surprising as Evers et al. [28] had shown that
sulﬁnpyrazone is a transported substrate of MRP2. Sub-
strates should compete with other substrates at high concen-
trations.
Huisman et al. [29] showed that stimulated transport by
MRP2 is not a peculiarity of the vesicular transport system,
because it also occurs in intact cells: they used MDCKII cells
transfected with a MRP2 construct and found that probenecid
stimulates transport of the HIV protease inhibitor saquinavir
by MRP2 up to 7-fold. Very high (10 mM) concentrations of
probenecid completely inhibited the stimulated transport.
Stimulation of MRP2-mediated transepithelial saquinavir
transport was also found for sulﬁnpyrazone [29] and sulfani-
tran [18], whereas probenecid can also strongly stimulate trans-
port of the taxanes paclitaxel and docetaxel by MRP2 [30].
These results show that the eﬀects of MRP2-stimulating drugs
could be clinically relevant and result in drug–drug interac-
tions aﬀecting plasma levels of taxanes or HIV protease inhib-
itors [30].Fig. 3. Concentration-dependent E217bG transport by MRP2 in the presenc
from Sf9 cell overproducing human MRP2. Taken from Zelcer et al. [11].The study of stimulated transport by MRP2 received a fur-
ther boost when Bodo et al. [17] and Zelcer et al. [18] indepen-
dently found an unusual substrate concentration dependence
of the transport of estradiol-17b-glucuronide (E217bG) by
MRP2. As shown in Fig. 3, a plot of initial transport rate ver-
sus substrate concentration shows an S-curve, rather than the
standard hyperbolic substrate saturation curve obtained thus
far for other MRPs. This suggested that substrate binds both
to the transport site and to a modulatory site which aﬀects
the transport rate allosterically by homotropic cooperative
interaction [18]. At 1 lM E217bG, transport by MRP2 is low
and this provided an opportunity to search for compounds
able to stimulate transport by binding to the putative modula-
tory site. Many were found [17,18]. These included compounds
found earlier [27] to stimulate NEM-GS transport, such as
penicillin G, sulﬁnpyrazone and probenicid, but also other
compounds such as pantoprazole, saquinavir, indomethacin,
furosemide, and glibenclamide. The most spectacular stimula-
tion (30-fold) was found with sulfanitran (Fig. 3). Several of
these stimulating compounds are known to be transported
MRP2 substrates themselves and one would expect them to in-
hibit transport at higher concentrations by competing with
E217bG for the substrate site. This was indeed observed for
indomethacin, glibenclamide and sulﬁnpyrazone (Fig. 4). Sul-
fanitran did not inhibit up to 1 mM (Fig. 4), but this com-
pound may not be transported at all by MRP2 [18]. This
also holds for ethinylestradiol-sulfate, which is also able to
stimulate E217bG transport >10-fold [31].
Bile salts also modestly stimulate E217bG transport 2–3-fold
[17,18] and inhibit at higher concentrations. Bodo et al. [17]
found that glycocholate transport was also stimulated about
2-fold by 100 lM E217bG. This led them to propose that bile
salts and E217bG are co-transported by MRP2 [17]. We prefere and absence of 1 mM sulfanitran. Transport was measured in vesicles
Fig. 4. Eﬀect of various compounds on E217bG transport. The
conditions were the same as in Fig. 3, but a ﬁxed 1 lM concentration
of E217bG was used.
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this point below.
Stimulation of MRP2-mediated transport is very dependent
on substrate. Only modest stimulatory eﬀects were observed
with 15 nM GS-DNP (maximally 3-fold), 100 lMMTX (max-
imally 2-fold), 4 lM NEM-GS (maximally 4-fold) [18,27], and
glutathionyl-ethacrynic acid [31]. More pronounced stimula-
tions were observed for transport of saquinavir [18,29] and tax-
anes [30] in intact cells, but these results are not directly
comparable with those of vesicular transport studies.
Not all known substrates of MRP2 are able to stimulate
E217bG transport. Notable exceptions are GSSG (Fig. 4)
and GS-DNP, which only inhibit and MTX, which has no ef-
fect at low E217bG concentrations, but inhibits transport at
saturating E217bG concentration, as expected. An interesting
compound without any eﬀect on transport of E217bG is
GSH (Fig. 4). This is in stark contrast to the pronounced stim-
ulatory eﬀect of GSH on transport of several substrates by
MRP1, as discussed in the preceding section. This contrast is
most strikingly illustrated by the transport of NNAL-O-gluc
by MRP1 and MRP2 [22]. Transport by MRP1 is completely
dependent on GSH (or analogs), whereas transport by MRP2
is nearly completely inhibited by 3 mM GSH.
Finally, we note that cooperativity has only been shown for
the MRP2 substrate E217bG. We expect some other substrates
to be able to stimulate their own transport as well, because
they bind with higher aﬃnity to the M site than to the S site,
but these remain to be found.7. MRP3
MRP3 is rather similar to MRP1 and MRP2 in putative
structure and in amino acid sequence. Like MRP1 and 2,
MRP3 is also able to transport compounds conjugated to
GSH, glucuronides or sulfate, but it appears to be unable to
transport GSH itself [32] under any condition, unlike MRP1,
2, 4 and 5. Most of the compounds found to stimulate
MRP1- or MRP2-mediated transport were found to have noeﬀect on MRP3, or to inhibit this transporter [18,30,33,34].
Sulfanitran, the most spectacular stimulator of the transport
of 1 lM E217bG by MRP2, stimulates transport by MRP3 less
than 2-fold [18]. The most substantial stimulation of MRP3-
mediated transport of E217bG was observed with benzbroma-
rone [34] and ethinylestradiol-sulfate [31], but it did not exceed
a factor 4. Interestingly, ethinylestradiol-sulfate completely
inhibits the stimulated transport at higher concentrations
[31]. This extends results obtained with MRP1 suggesting that
compounds that do not appear to be transported at all can
nevertheless inhibit transport of other substrates.8. MRP4
Lai et al. [35] reported that MRP4-mediated export of
cAMP from intact cells was inhibited by GSH depletion and
they also found increased sensitivity in depleted cells to drugs
exported by MRP4. In contrast, we have not found any eﬀect
of GSH depletion on MRP4-mediated cyclic nucleotide export
from HEK293 cells [36] and we have not observed any require-
ment for GSH in vesicular transport by MRP4 of steroid- and
bile acid-conjugates [23] or prostaglandins E1 and E2 [37].
More recently, however, Rius et al. [38] discovered that the
mono-anionic bile salt taurocholate is only transported by
MRP4 in the presence of GSH. Just as in the case of GSH-
stimulated transport by MRP1, the GSH could be replaced
by the GSH analogs methyl-SG and ophthalmic acid. Trans-
port was inhibited by several other mono-anionic bile salts,
not available in radioactive form, suggesting that MRP4 is a
general mono-anionic bile salt transporter if GSH is present.
Interestingly, Rius et al. [38] also found transport of labeled
GSH in the presence of 5 lM taurocholate; no transport of
GSH was found in the absence of taurocholate. The authors
calculate that their rate of GSH transport in the presence of
taurocholate is similar to the rate of transport of taurocholate
in the presence of GSH and they conclude that ‘‘these rates are
consistent with co-transport of GSH and taurocholate’’ [38].
However, they only measured GSH transport at a single con-
centration of taurocholate. This is inadequate in our opinion
to decide whether stimulated transport could be co-transport
or not. There were also technical problems in the assay, as
the authors emphasize themselves: at a concentration of
5 mM radioactive GSH the background is enormous and
about 70% of the actual reaction measured. It remains there-
fore unclear how much taurocholate stimulates GSH transport
in this system, and what the dependence of the stimulation is
on taurocholate concentration. Furthermore, a peculiarity of
the Chinese hamster lung ﬁbroblast V79 cell system used by
Rius et al. [38] should be mentioned here: The rate of tauro-
cholate transport (in the presence of GSH) was only 2-fold
higher in the MRP4 transfectants than in the control cells.
The Km values for taurocholate and GSH (for taurocholate
transport) of the transfectants and control cells are similar,
and Rius et al. [38] therefore do not correct their transfectant
values for the rates found in the control cells. However, they
clearly show that GSH transport in the control cells in the
presence of taurocholate was 7-fold lower (rather than 2-fold
lower) than in the transfectants. Hence, there is an obvious
problem in determining the stoichiometry of GSH and tauro-
cholate transport given the very diﬀerent contribution of con-
trol cells and transfectants to GSH and taurocholate transport.
1090 P. Borst et al. / FEBS Letters 580 (2006) 1085–1093On the basis of these arguments, we consider the conclusion
that MRP4 co-transports GSH with monoanionic bile salts
[38] not adequately supported by data.
In a recent paper Van Aubel et al. [39] report (vesicular)
transport of urate by MRP4. They conclude that transport
shows homotropic cooperativity with a Hill coeﬃcient of 1.7.
Whereas urate inhibited MTX transport, it stimulated cGMP
transport nearly 2-fold. The authors also conclude that cGMP
transport shows homotropic cooperativity and that this is
abolished by urate stimulation. We ﬁnd these results hard to
interpret. Urate transport by MRP4 is only twice the (high)
background transport rate in the Sf9 system. It is impossible
in our opinion/experience to draw such far-reaching conclu-
sions from such experimental data. Moreover, substantial
cooperativity has not been observed for the high cGMP trans-
port by human erythrocyte vesicles [40], which is due to MRP4
(H. Yamaguchi, C. de Wolf and P. Borst, unpublished).9. MRP5–8
For MRP5, 6, and 7 no evidence for stimulated transport
has been reported, but the issue has not been pushed. As far
as we know, no systematic attempt has been made to look
for stimulatory eﬀects on these transporters in the same way
as done for MRP1 and MRP2. Chen et al. [41] recently re-
ported that transport of 1 lM E217bG by MRP8 is stimulated
up to 6-fold by dehydroepiandrosterone-3-sulfate (DHEAS)
and to a lesser extent by some other steroid sulfate. DHEAS
is also a substrate of MRP8, but its transport is not stimulated
by E217bG.10. At MRP2
The Arabidopsis thaliana vacuolar MRP, At MRP2, has been
studied in detail by Liu et al. [42]. Interestingly, they found that
this plant MRP transports E217bG and that transport is stimu-
lated by glutathionyl-dinitrophenol (DNP-GS), the stimulation
mainly being due to a lowering ofKm (3-fold)with little eﬀect on
Vmax. Conversely, E217bGdecreased theKm forDNP-GS 5-fold
without eﬀect on Vmax. Whereas GSH also stimulated E217bG
transport, E217bG completely inhibited GSH transport. The
authors conclude from these and many other experiments that
DNP-GS and E217bG are not co-transported, but that these
substrates stimulate ‘‘each other’s transport via distinct but cou-
pled binding sites [42] The authors comeupwith a complexmod-
el for AtMRP with 4 transport and 3 allosteric sites. We think,
however, that the model in Fig. 4 with one promiscuous binding
site allowing binding of multiple ligands in (partially overlap-
ping) sites can explain their data.11. Is there hard evidence for co-transport of substrates by
MRPs?
It should be clear from the model section that co-transport
(model A in Fig. 1) is hard to prove, because model B often pro-
vides a satisfactory explanation for the stimulated transport
observed (Fig. 2). Conversely, it is hard to disprove that co-
transport exists, as the predictions of the co-transport modelare not strong. Nevertheless, we are going to argue here that
all data purporting to show co-transport fail to make the point.
For MRP1 the possibility of co-transport was ﬁrst evoked
by Loe et al. [15]. They found cross-stimulation of vincristine
(VCR) and GSH in vesicular transport studies, but were care-
ful to point out the pitfalls in the co-transport interpretation:
‘‘Reliable estimation of the stoichiometry of VCR and GSH
transport is diﬃcult because of the extremely brief period for
which VCR uptake is linear. However, if the GSH-stimulated
uptake of VCR at the earliest time point of 8 s is taken as a
minimal estimate of initial rate, a value of 20 pmol/min/mg
is obtained. This is approximately the same as the rate of up-
take of GSH uptake calculated over a 5-min period. In addi-
tion to the caveat mentioned above, these data are based on
determinations at only one concentration of drug and GSH.
Consequently, they are certainly not suﬃciently reliable to
conclude that there is a 1:1 stoichiometry with respect to
GSH and VCR transport. However, they do indicate that
the transport rates of both compounds are not vastly diﬀerent,
and that a true cotransport mechanism may be involved.’’ [15].
Nearly all subsequent experiments showing stimulated trans-
port by MRP1, did not ﬁt the co-transport model at all, as dis-
cussed in Ref. [13], and with hindsight it seems likely that the
VCR-GSH cross-stimulation is an example of model B in
Fig. 2, in which the rates of transport of S and M happened
to be similar at the drug concentrations chosen.
The apparent co-transport of GSH and bile salt by MRP4
has been discussed in Section 8. The only other example of
possible co-transport comes from our lab. Evers et al. [28]
studied transepithelial vinblastine (VBL) transport mediated
by MRP2 in MDCKII cell monolayers and noted an increased
eﬄux of GSH stimulated by VBL. Over a VBL concentration
range of 10–50 lM they found a more or less constant ratio of
VBL/GSH transport varying between 2.1 and 3.1. This is the
only case in the literature in which a constant ratio of drug/
GSH transport was found over a range of drug concentrations.
Evers et al. [28] tentatively concluded that ‘‘transport of VBL
is associated with GSH export.’’ They attributed the high
VBL/GSH ratio to technical problems in determining the exact
rate of VBL transport, caused by the high diﬀusion rate of the
relatively hydrophobic VBL through the plasma membrane.
With hindsight, however, the results of Evers et al. [28] with
VBL can also be explained with model B of Fig. 1 and some of
their other results actually ﬁt model B better than model A of
Fig. 1. For instance, low concentrations of sulﬁnpyrazone
stimulate apical GSH eﬄux from the MDCKII-MRP2 mono-
layer, but higher concentrations completely inhibit GSH eﬄux,
whereas drug transport is still going up. This can be explained
[28] by assuming that sulﬁnpyrazone can bind to both M and S
sites and displaces GSH at S at high drug concentrations.
Membrane eﬀects (Figs. 1 and 2C) should be kept in mind as
an important confounder, but they do not provide a plausible
explanation for apparent co-transport, as it is hard to see
why substrate S cannot stimulate its own transport by the same
membrane eﬀects that it contributes to transport of M. How-
ever, apparent homotropic cooperativity, as observed in the
transport of E217bG by MRP2, could in principle also be
caused by membrane eﬀects rather than by model B. The fact
that rat Mrp2 shows much less cooperativity [43] than human
MRP2 when transporting E217bG in Sf9 cell membranes, is
more easily explained by model B, however, although the minor
diﬀerences in the results for rat Mrp2 reported from diﬀerent
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in growth conditions of the Sf9 cells.12. The potential physiological signiﬁcance of stimulated
transport by MRPs
Substantial stimulated transport has been found for MRP1,
MRP2 and MRP4 and signiﬁcant eﬀects have been observed
for MRP3. Given the apparent similarity in overall topology
and function of MRPs, we expect that some form of stimulated
transport will be found for each MRP, but a more systematic
search still needs to be done. How large the eﬀects could be
in vivo, is still anybody’s guess, even in the two cases studied
most, MPR1 and MRP2. The clear stimulation of bile ﬂow in
the rat by benzylpenicillin, presumably due to stimulated trans-
port of GSH byMrp2 as the eﬀect is absent inMrp2 null rats, is
one example of stimulated transport in an intact animal [44].
More might be uncovered by directed searches. If transport
of compound S is totally dependent on the presence of a mod-
ulator M that is not routinely tested, as is done for GSH, trans-
port of S may be missed in vesicular transport assays.
Much more work is required to understand the evolution of
stimulated transport. A case in point is the stimulated trans-
port of E217bG by human MRP2 (Figs. 3 and 4). As men-
tioned above and discussed in detail elsewhere [43], the
striking homotropic cooperativity of the human MRP2
(Fig. 3) is hardly present in rat Mrp2, and the 30-fold stimula-
tion of transport of low concentrations of E217bG by com-
pounds like sulfanitran (Fig. 1) is reduced to 1.5-fold for rat
Mrp2 (our unpublished results). One could argue that this re-
sult shows that stimulated transport is not important, because
it is not conserved between rat and man. In contrast, we think
that the rat–human comparison shows that stimulated trans-
port is not an unavoidable consequence of MRP2 transport
properties, but something selected for in human evolution.
So what is the selection process? What could be the advan-
tage of stimulated transport? Some inspiration may come from
the P450 system. The allosteric phenomena in cytochrome
P450-catalyzed mono-oxygenation have been studied in detail
[45] and interpreted on the basis of available crystal structures
of bacterial P450 isoforms [46]. The most abundant P450 iso-
form metabolizing xenobiotics in human liver, P450 3A4,
shows homotropic cooperativity towards several steroids. Het-
erotropic cooperative eﬀects on steroid oxidation have been ob-
served with other steroids and with unrelated compounds, such
as a-naphthoﬂavone. Two models have been proposed to ex-
plain the cooperative eﬀects: one with a distinct allosteric site,
the other in which substrate and activator bind simultaneously
to the same active site, changing the dimensions of the site and
the position of the substrate: both the crystallographic analysis
of protein–ligand complexes [46] and mutagenesis studies [47]
support the second model. Especially persuasive are the muta-
genesis studies of Harlow and Halpert [47]. By replacing resi-
dues in the active site of P450 3A4 thought to bind
modulator by more bulky residues, they were able to abolish
homo- and heterotropic cooperativity and create an enzyme
that displayed hyperbolic steroid hydroxylation kinetics.
There is ample evidence for allosteric eﬀects on P450-cata-
lyzed reactions in vivo [45,48] and it is therefore reasonable
to ask why nature opts for such a complex mechanism to dis-
pose of xenotoxins and endogenous metabolites. This questionwas addressed in depth by Atkins et al. [49]. They argue
‘‘. . .that detoxiﬁcation enzymes such as CYPs may evolve,
not only to metabolize a wide range of structurally unrelated
xenobiotics, but also to minimize the probability of bioactiva-
tion of previously unencountered xenobiotics by distributing
the toxic load into multiple products.’’ Atkins et al. [49] refer
‘‘to this probabilistic process as ‘‘distributive catalysis.’’ Dis-
tributive catalysis will provide a detoxiﬁcation advantage if
the toxicity of a compound and its metabolites exhibit sublin-
ear, or threshold, dose–response relationships. In that case a
low rate of oxidation may distribute the toxin load between
unaltered toxin and toxic metabolites in such a fashion that
the toxicity of the sum is less than that of the same concentra-
tion of unaltered toxin or metabolite. At high toxin concentra-
tions the distributive advantage is best accomplished with
faster turn-over, as achieved by allostery’’ [49]. Atkins et al.
[49] provide detailed calculations to show that allosteric sys-
tems can indeed provide toxicological advantages if the toxin
and its metabolites exhibit threshold (or sublinear) dose–
response relationships. The advantages are modest, however,
and they only exist over a limited toxin concentration range.
It is not obvious to us that such a complex mechanism would
be selected in evolution on this modest basis.
How do these P450 considerations translate to MRPs?
Transporters are no oxygenases, but the common theme is pro-
miscuity and the risk it entails. With P450 it is the generation
of toxic compounds from innocuous ones; with MRPs it is the
risk of exporting useful compounds from the cell in addition to
waste products, toxins, drug conjugates, etc. Homotropic
cooperativity would limit loss of valuable organic anions, het-
erotropic cross-stimulation of transport of toxic compounds
would help to limit the total toxin load [33].
These considerations do not explain why MRPs can be acti-
vated by compounds that they do not seem to transport at all,
like the stimulation of E217bG transport by sulfanitran (Fig. 3).
It is possible that there are endogenous compounds of this class
that stimulate as well, as several aromatic compounds with a
sulfoxide (S‚O) or tosyl (O‚S‚O) group were found to stim-
ulate MRP2-mediated transport, e.g., sulﬁnpyrazone and gli-
benclamide (Fig. 4). However, another simpler explanation
would be that the selection in evolution is not for transport reg-
ulation, but for a promiscuous binding site accommodating a
large range of compounds. Binding compound M in this site
may improve binding of S. This could occur in several diﬀerent
ways: M could provide additional interaction sites for S, it
could shield residues unfavorable for binding S, or M could af-
fect the binding site of S allosterically.
This model leans heavily on the results obtained with P450,
which documents a single cavity in which S and M (or S1 and
S2) reside together. However, our interpretation is very diﬀer-
ent from that of Atkins et al. [49]: it is not toxicological sophis-
tication that drives the evolution of a binding site that can
accommodate more than one ligand, but the inability of nature
to create a promiscuous binding site that binds only one ligand
at a time. Although space does not permit the discussion of bac-
terial systems with promiscuous drug binding sites, the results
obtained in these systems ﬁt the interpretation oﬀered here.
This holds both for pumps, for which cooperative drug binding
has been shown [50] and for the repressors that control the syn-
thesis of the pumps. These repressors bind the same range of
drugs as the pumps they control and their promiscuous binding
sites have been studied in detail by crystallography [51].
1092 P. Borst et al. / FEBS Letters 580 (2006) 1085–1093The interpretation oﬀered here for stimulated transport is
compatible with all published data. Whether an allosteric site
is separate from the substrate binding site, or part of a larger
substrate binding site, does not have any consequences for
transport kinetics. Both models can fully account for homo-
and heterotropic cooperativity, as discussed in the P450 litera-
ture, and for modulator eﬀects on Km and Vmax of substrate.
The essential diﬀerence between the two models is that a sep-
arate allosteric site must have been selected for its regulatory
advantages, whereas a site that is part of the substrate site
might have arisen as byproduct of the selection for a large pro-
miscuous substrate-binding site. For the moment we prefer the
second one, because it is the simpler one.
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